Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Screening for noncardia gastric cancer may be costeffective

Screening for noncardia gastric cancer may be costeffective PharmacoEconomics & Outcomes News 804, p30 - 2 Jun 2018 Screening for noncardia gastric cancer may be cost effective Endoscopic screening for noncardia gastric adenocarcinoma (NCGA) appears to be cost effective for ethnic groups in the US, according to findings of a study published in Gastroenterology. A Markov model was used to compare the cost effectiveness of a no screening (current standard) for noncardia gastric cancer, or one of two endoscopic screening stategies at the time of screening colonoscopy in 50-year-old non-Hispanic Whites, non-Hispanic Blacks, Hispanics or Asians: upper endoscopy (esophagogastroduodenoscopy [EGD]) with biopsies and continued surveillance in patients with intestinal metaplasia or severe pathology; or EGD with biopsies every two years. Cost effectiveness was assessed from a US healthcare perspective over a 30-year time horizon. The estimated incremental cost effectiveness ratio of EGD screening with surveillance if indicated, compared with no screening or biennial screening, was $122 428 per QALY gained in non-Hispanic Whites, $80 278 per QALY in non-Hispanic Blacks, $76 070 per QALY gained in Hispanics and $71 451 per QALY gained in Asians. EGD screening with surveillance if indicated was therefore cost effective at a willingness-to-pay threshold of $100 000 per QALY gained in non-Hispanic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Screening for noncardia gastric cancer may be costeffective

PharmacoEconomics & Outcomes News , Volume 804 (1) – Jun 2, 2018
Download PDF
1 page

Screening for noncardia gastric cancer may be costeffective

Abstract

PharmacoEconomics & Outcomes News 804, p30 - 2 Jun 2018 Screening for noncardia gastric cancer may be cost effective Endoscopic screening for noncardia gastric adenocarcinoma (NCGA) appears to be cost effective for ethnic groups in the US, according to findings of a study published in Gastroenterology. A Markov model was used to compare the cost effectiveness of a no screening (current standard) for noncardia gastric cancer, or one of two endoscopic screening stategies at the time of...
Loading next page...
1
 
/lp/springer_journal/screening-for-noncardia-gastric-cancer-may-be-costeffective-yxgk0zukv5

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-018-4994-z
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p30 - 2 Jun 2018 Screening for noncardia gastric cancer may be cost effective Endoscopic screening for noncardia gastric adenocarcinoma (NCGA) appears to be cost effective for ethnic groups in the US, according to findings of a study published in Gastroenterology. A Markov model was used to compare the cost effectiveness of a no screening (current standard) for noncardia gastric cancer, or one of two endoscopic screening stategies at the time of screening colonoscopy in 50-year-old non-Hispanic Whites, non-Hispanic Blacks, Hispanics or Asians: upper endoscopy (esophagogastroduodenoscopy [EGD]) with biopsies and continued surveillance in patients with intestinal metaplasia or severe pathology; or EGD with biopsies every two years. Cost effectiveness was assessed from a US healthcare perspective over a 30-year time horizon. The estimated incremental cost effectiveness ratio of EGD screening with surveillance if indicated, compared with no screening or biennial screening, was $122 428 per QALY gained in non-Hispanic Whites, $80 278 per QALY in non-Hispanic Blacks, $76 070 per QALY gained in Hispanics and $71 451 per QALY gained in Asians. EGD screening with surveillance if indicated was therefore cost effective at a willingness-to-pay threshold of $100 000 per QALY gained in non-Hispanic

Journal

PharmacoEconomics & Outcomes News – Springer Journals

Published: Jun 2, 2018

There are no references for this article.